Carl E Clarke
A5005665397- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Dysphagia Assessment and Management
- Voice and Speech Disorders
- Cerebral Palsy and Movement Disorders
- Parkinson's Disease and Spinal Disorders
- Neurological diseases and metabolism
- Autism Spectrum Disorder Research
- Health Systems, Economic Evaluations, Quality of Life
- Genetic Neurodegenerative Diseases
- Cerebral Venous Sinus Thrombosis
- RNA regulation and disease
- Neuroscience and Neuropharmacology Research
- Nuclear Receptors and Signaling
- Migraine and Headache Studies
- Neurogenetic and Muscular Disorders Research
- Nutrition, Genetics, and Disease
- Genetic Associations and Epidemiology
- Stuttering Research and Treatment
- Restless Legs Syndrome Research
- Genomic variations and chromosomal abnormalities
- Balance, Gait, and Falls Prevention
- Glaucoma and retinal disorders
- Lysosomal Storage Disorders Research
University College London
2010-2025
University of Birmingham
2014-2024
Sandwell & West Birmingham Hospitals NHS Trust
2014-2024
Birmingham City Hospital
2007-2024
Inserm
2022-2024
Centre de recherche en Epidémiologie et Santé des Populations
2022-2024
Université de Versailles Saint-Quentin-en-Yvelines
2022-2024
Université Paris-Saclay
2022-2024
Center for Human Genetics
2024
Hertie Institute for Clinical Brain Research
2012-2022
There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.
Mutations in the glucocerebrosidase gene (GBA), which cause Gaucher disease, are also potent risk factors for Parkinson's disease. We examined whether a genetic burden of variants other lysosomal storage disorder genes is more broadly associated with disease susceptibility. The sequence kernel association test was used to interrogate variant among 54 genes, leveraging whole exome sequencing data from 1156 cases and 1679 control subjects. discovered significant rare, likely damaging risk....
Significance Understanding loci nominated by genome-wide association studies (GWASs) is challenging. Here, we show, using the specific example of Parkinson disease, that identification protein–protein interactions can help determine most likely candidate for several GWAS loci. This result illustrates a significant general principle will apply across multiple diseases.
<h3>Abstract</h3> Nuclei within cells are constantly subjected to compressive, tensile and shear forces, which regulate nucleoskeletal cytoskeletal remodeling, activate signaling pathways direct cell-fate decisions. Multiple rheological methods have been adapted for characterizing the response applied forces of isolated nuclei intact cells. However, <i>in vitro</i> measurements fail capture viscoelastic modulation nuclear stress-strain relationships by physiological tethering surrounding...
Parkinson's disease is a neurodegenerative movement disorder that currently has no disease-modifying treatment, partly owing to inefficiencies in drug target identification and validation. We use Mendelian randomization investigate over 3,000 genes encode druggable proteins predict their efficacy as targets for disease. expression protein quantitative trait loci mimic exposure medications, we examine the causal effect on risk (in two large cohorts), age at onset progression. propose 23...
Rotigotine is a new, non-ergot dopamine agonist formulated in transdermal delivery system. The present study was to investigate the efficacy and safety of rotigotine patch treatment early Parkinson's disease. Patients (n = 561) were randomized rotigotine, ropinirole, or placebo. titration period up 13 weeks, there minimum dose-maintenance 24 weeks for ropinirole 33 rotigotine. primary endpoint proportion patients with 20% decrease combined Unified Disease Rating Scale Part II III scores....
We performed a genome-wide association study (GWAS) in 1705 Parkinson's disease (PD) UK patients and 5175 controls, the largest sample size so far for PD GWAS. Replication was attempted an additional cohort of 1039 French cases 1984 controls 27 regions showing strongest evidence (P< 10−4). replicated published associations 4q22/SNCA 17q21/MAPT chromosome 10−10) found independent 4q22/SNCA. A detailed analysis haplotype structure at 17q21 showed that there are three separate risk groups...
The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries PD patients various degrees motor complications examined the effects dyskinesias on quality life (QoL) and health care costs. Retrospective prospective economic data were collected, QoL was measured using Short Form-36 (SF-36) Quality Life (PDQL) Scale. Regression analysis used estimate adjusted costs, whilst accounting for...
Objectives This priority setting partnership was commissioned by Parkinson's UK to encourage people with direct and personal experience of the condition work together identify prioritise top 10 evidential uncertainties that impact on everyday clinical practice for management disease (PD). Setting The UK. Participants Anyone PD including: (PwP), carers, family friends, healthcare social care professionals. Non-clinical researchers employees pharmaceutical or medical devices companies were...
Eleven genetic loci have reached genome-wide significance in a recent meta-analysis of association studies Parkinson disease (PD) based on populations Caucasian descent. The extent to which these effects are consistent across different is unknown.Investigators from the Genetic Epidemiology Parkinson's Disease Consortium were invited participate study. A total 11 SNPs genotyped 8,750 cases and 8,955 controls. Fixed as well random models used provide summary risk estimates for variants. We...